Quinoline-3-carboxamides Such As Tasquinimod Are Not Specific Inhibitors of S100A9

Overview

Journal Blood Adv

Specialty Hematology

Date 2018 May 24

PMID 29789315

Citations 6

Authors

Martin Pelletier

Jean-Christophe Simard

Denis Girard

Philippe A Tessier

Affiliations

Soon will be listed here.

Citing Articles

Blocking S100A9-signaling is detrimental to the initiation of anti-tumor immunity.

Demir M, Lin Y, Costa Cruz P, Tajima M, Honjo T, Muller E Front Immunol. 2024; 15:1479502.

PMID: 39497822 PMC: 11532050. DOI: 10.3389/fimmu.2024.1479502.

Endogenous Ligands of TLR4 in Microglia: Potential Targets for Related Neurological Diseases.

Chen B, Di B Curr Drug Targets. 2024; 25(14):953-970.

PMID: 39234911 DOI: 10.2174/0113894501316051240821060249.

S100A9: The Unusual Suspect Connecting Viral Infection and Inflammation.

Boucher J, Gilbert C, Bose S, Tessier P J Immunol. 2024; 212(10):1523-1529.

PMID: 38709994 PMC: 11076006. DOI: 10.4049/jimmunol.2300640.

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.

Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A J Immunother Cancer. 2023; 11(1).

PMID: 36650020 PMC: 9853259. DOI: 10.1136/jitc-2022-005319.

DAMPening Mortality in COVID-19: Therapeutic Insights From Basic Cardiometabolic Studies on S100A8/A9.

Hanssen N, Spaetgens B, Nagareddy P, Murphy A Circulation. 2021; 143(10):971-973.

PMID: 33434052 PMC: 7940571. DOI: 10.1161/CIRCULATIONAHA.120.053025.

References

Isaacs J, Pili R, Qian D, Dalrymple S, Garrison J, Kyprianou N . Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006; 66(16):1768-78. DOI: 10.1002/pros.20509. View

Olsson A, Bjork A, Vallon-Christersson J, Isaacs J, Leanderson T . Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer. 2010; 9:107. PMC: 2885345. DOI: 10.1186/1476-4598-9-107. View

Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A . Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009; 7(4):e97. PMC: 2671563. DOI: 10.1371/journal.pbio.1000097. View

Gupta N, Al Ustwani O, Shen L, Pili R . Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. Onco Targets Ther. 2014; 7:223-34. PMC: 3928061. DOI: 10.2147/OTT.S53524. View

Yoshioka Y, Mizutani T, Mizuta S, Miyamoto A, Murata S, Ano T . Neutrophils and the S100A9 protein critically regulate granuloma formation. Blood Adv. 2018; 1(3):184-192. PMC: 5737174. DOI: 10.1182/bloodadvances.2016000497. View